References
- Viaud S, Saccheri F, Mignot Gg, Yamazaki T, Daillère R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013; 342:971-6; PMID:24264990; http://dx.doi.org/10.1126/science.1240537
- Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, Molina DA, Salcedo R, Back T, Cramer S et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013; 342:967-70; PMID:24264989; http://dx.doi.org/10.1126/science.1240527
- Casanova JL, Abel L, Quintana-Murci L. Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Ann Rev Immunol 2010; 29:447-91; PMID: 21219179; http://dx.doi.org/10.1146/annurev-immunol-030409-101335
- Hawn T, Verbon A, Lettinga K, Zhao L, Li S, Laws RJ, Skerrett SJ, Beutler B, Schroeder L, Nachman A et al. A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires' disease. J Exp Med 2003; 198:1563-72; PMID:14623910; http://dx.doi.org/10.1084/jem.20031220
- Rutkowski MR, Stephen TL, Svoronos N, Allegrezza MJ, Tesone AJ, Perales-Puchalt A, Perales-Puchalt A, Brencicova E, Escovar-Fadul X, Nguyen JM et al. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell 2015; 27:27-40; PMID:25533336; http://dx.doi.org/10.1016/j.ccell.2014.11.009
- Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, Sitaraman SV, Knight R, Ley RE, Gewirtz AT. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010; 328:228-31; PMID:20203013; http://dx.doi.org/10.1126/science.1179721
- Letran SE, Lee S-JJ, Atif SM, Flores-Langarica A, Uematsu S, Akira S, Cunningham AF, McSorley SJ. TLR5-deficient mice lack basal inflammatory and metabolic defects but exhibit impaired CD4 T cell responses to a flagellated pathogen. J Immunol 2011; 186:5406-12; PMID:21451112; http://dx.doi.org/10.4049/jimmunol.1003576
- Rabinovich GA. Galectin-1 as a potential cancer target. Br J Cancer 2005; 92:1188-92; PMID:15785741; http://dx.doi.org/10.1038/sj.bjc.6602493
- Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009; 114:1141-9; PMID:19470694; http://dx.doi.org/10.1182/blood-2009-03-208249
- Chen W-C, Lai Y-H, Chen H-Y, Guo H-R, Su I-J, Chen H. Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor. Histopathol 2013; 63:225-33; PMID:23738752; http://dx.doi.org/10.1111/his.12156